Skinvisible

Skinvisible Financial Debt Ratio

The Financial Debt Ratio of Skinvisible (SKVI) as of Nov 2, 2026 is 4,211.44 %. In the previous year, Financial Debt Ratio was 3,618.12 % — a change of 16.40% (higher).

Financial Debt Ratio

4,211.44 %

YoY

16.40%

Last updated:

Financial Debt Ratio of Skinvisible is 2025 4,211.44 % . Financial Debt Ratio of Skinvisible was 2024 3,618.12 % . It decreases by 16.40% higher compared to the previous year.

The Skinvisible Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
1,277.58 USD
Jan 1, 2019
511.23 USD
Jan 1, 2020
459.74 USD
Jan 1, 2021
1,135.83 USD
Jan 1, 2022
1,313.82 USD
Jan 1, 2023
3,483.48 USD
Jan 1, 2024
3,618.12 USD
Jan 1, 2025
4,211.44 USD
The Skinvisible Financial Debt Ratio history
YEARFinancial Debt RatioYoY
4,211.44 %+16.40%
3,618.12 %+3.87%
3,483.48 %+165.14%
1,313.82 %+15.67%
1,135.83 %+147.06%
459.74 %-10.07%
511.23 %-59.98%
1,277.58 %+51.96%
840.73 %-41.18%
1,429.36 %+84.76%
773.64 %+0.11%
772.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Skinvisible Stock analysis

What does Skinvisible do? Skinvisible Inc develops and patents the Invisicare polymer delivery system, which enhances the delivery of active ingredients in topical skin care products. The company has formulated over forty topical skin products using Invisicare, with Pivotal being the patented technology that enables extended duration of active ingredients on the skin. Invisicare specifically carries water-insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or organic solvents. The firm's revenue comes from licensing the Invisicare technology to partners who develop and sell skin care products incorporating this delivery system. Skinvisible Inc's primary customers are pharmaceutical and cosmetic companies seeking to improve the efficacy of their topical skin care formulations. These companies purchase the Invisicare technology to integrate into their own product lines, leveraging the extended delivery duration and compatibility with water-based formulations. The company does not sell end-user products but focuses on technology licensing for partners who manufacture and market the final skin care products. The business model relies on the patent protection of Invisicare, which allows Skinvisible to generate revenue through licensing agreements. Partners pay for the right to use the technology in their products, with the company's focus on developing and protecting the polymer delivery system as its core asset. The firm's product portfolio includes over forty topical skin products developed using Invisicare, but these are not sold directly by Skinvisible Inc. Skinvisible is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Skinvisible stock

Financial Debt Ratio of Skinvisible is 4,211.44 % in 2025.

Financial Debt Ratio of Skinvisible changed from 3,618.12 % to 4,211.44 %, representing a 16.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Skinvisible since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Skinvisible with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Skinvisible

All Key Metrics — Skinvisible